Current and future treatments of HIV-associated dyslipidemia

Bibliography

• UNAIDS: AIDS epidemic update. (2007)
   Google Scholar
• Grunfeld C, Kotler DP, Shigenaga JK et al.: Circulating interferon-levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 90, 154–162 (1991)
   Google Scholar
• Grunfeld C, Kotler DP, Hamadeh R, Tierney A , Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86, 27–31 (1989)
   Google Scholar
• Hellerstein MK, Grunfeld C, Wu K et al.: Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 76, 559–565 (1993)
   Google Scholar
• Shor-Posner G, Basit A, Lu Y et al.: Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am. J. Med. 94, 515–519 (1993)
   Google Scholar
• Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab. 76, 1423–1427 (1993)
   Google Scholar
• Periard D, Telenti A, Sudre P et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100, 700–705 (1999)
   Google Scholar
• Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J: Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352, 1031–1032 (1998)
   Google Scholar
• Mulligan K, Grunfeld C, Tai VW et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23, 35–43 (2000)
   Google Scholar
• Petit JM, Duong M, Duvillard L et al.: HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm. Metab. Res. 32, 367–372 (2000)
   Google Scholar
• Purnell JQ, Zambon A, Knopp RH et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14, 51–57 (2000)
   Google Scholar
• Dube MP, Qian D, Edmondson-Melancon H et al.: Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin. Infect. Dis. 35, 475–481 (2002)
   Google Scholar
• Montes ML, Pulido F, Barros C et al.: Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J. Antimicrob. Chemother. 55, 800–804 (2005)
   Google Scholar
• Friis-Moller N, Weber R, Reiss P et al.: Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179–1193 (2003)
   Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093–2099 (1999)
   Google Scholar
• Stein JH, Klein MA, Bellehumeur JL et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104, 257–262 (2001)
   Google Scholar
• Carr A, Samaras K, Burton S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51–F58 (1998)
   Google Scholar
• Behrens G, Dejam A, Schmidt H et al.: Impaired glucose tolerance, cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13, F63–F70 (1999)
   Google Scholar
• Hammer SM, Saag MS, Schechter M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296, 827–843 (2006).
   Google Scholar
• Current guidelines for the treatment of adult HIV infection from the International AIDS society.
   Google Scholar
• Shafran SD, Mashinter LD, Roberts SE: The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6, 421–425 (2005)
   Google Scholar
• Sanne I, Piliero P, Squires K, Thiry A, Schnittman S: Results of a Phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune Defic. Syndr. 32, 18–29 (2003)
   Google Scholar
• Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D: Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 47(2), 161–167 (2008)
   Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20, 711–718 (2006)
   Google Scholar
• Young J, Weber R, Rickenbach M et al.: Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir. Ther. 10, 585–591 (2005)
   Google Scholar
• Liang JS, Distler O, Cooper DA et al.: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med. 7, 1327–1331 (2001)
   Google Scholar
• Nolan D: Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63, 2555–2574 (2003)
   Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I et al.: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy. AIDS 13, 1659–1667 (1999)
   Google Scholar
• Anastos K, Lu D, Shi Q et al.: Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J. Acquir. Immune Defic. Syndr. 45, 34–42 (2007)
   Google Scholar
• Fellay J, Boubaker K, Ledergerber B et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 1322–1327 (2001)
   Google Scholar
• Galli M, Ridolfo AL, Adorni F et al.: Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 29, 21–31 (2002)
   Google Scholar
• van Leth F, Phanuphak P, Stroes E et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviraltherapy- naive patients infected with HIV-1. PLoS Med. 1, E19 (2004)
   Google Scholar
• Riddler S, Haubrich R, DiRienzo G: A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infections – ACTG 5142. Presented at: XVI International AIDS Conference. Toronto, Canada, 13–18 August (2006) (Abstract THLB0204)
   Google Scholar
• Haubrich R, Riddler S, DiRenzo G: Metabolic outcomes of ACTG 5142: a prospective, randomized, Phase III trial of NRTI-, PI-, NNRTI-sparing regimens for intial treatment of HIV-1 infection. Presented at: The 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February (2007) (Abstract 38)
   Google Scholar
• Villarroe M, Martinez E, Riba N, Leon A, Manrique M: Lack of metabolic abnormalities and mitochondrial toxicity with enfuvirtide (T-20): a double-blind, placebo-controlled, crossover study with random sequence assignation in healthy adult volunteers. Presented at: The 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Sydney, Australia, 19–21 July (2007) Abstract.
   Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, Samore M: Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch. Intern. Med. 160, 2050–2056 (2000)
   Google Scholar
• Friis-Moller N, Sabin CA, Weber R et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993–2003 (2003).
   Google Scholar
• This large cohort study (known as the DAD study) was crucial in the link of antiretroviral therapy and the risk of myocardial infarction.
   Google Scholar
• Friis-Moller N, Reiss P, Sabin CA et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723–1735 (2007).
   Google Scholar
• Update of the DAD study, which shows how the risk of myocardial infarction has changed over time in patients with HIV.
   Google Scholar
• Holmberg SD, Moorman AC, Greenberg AE: Trends in rates of myocardial infarction among patients with HIV. N. Engl. J. Med. 350, 730–732; author reply 730–732 (2004)
   Google Scholar
• Klein D, Hurley LB, Quesenberry CP Jr, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. 30, 471–477 (2002)
   Google Scholar
• Grover SA, Coupal L, Gilmore N, Mukherjee J: Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Am. J. Cardiol. 95, 586–591 (2005)
   Google Scholar
• McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society: Canadian Cardiovascular Society position statement – recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol. 22, 913–927 (2006).
   Google Scholar
• Current guidelines for the diagnosis and treatment of dyslipidemia and the prevention of cardiovascular disease from the Canadian Cardiovascular Society.
   Google Scholar
• Law MG, Friis-Moller N, El-Sadr WM et al.: The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 7, 218–230 (2006)
   Google Scholar
• Dube MP, Stein JH, Aberg JA et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37, 613–627 (2003).
   Google Scholar
• Current guidelines for the evaluation and management of dyslipidemia in HIV-positive adults from the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
   Google Scholar
• Schambelan M, Benson CA, Carr A et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Acquir. Immune Defic. Syndr. 31, 257–275 (2002).
   Google Scholar
• Current guidelines for the evaluation and management of dyslipidemia in HIV-positive adults from the International AIDS Society.
   Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
   Google Scholar
• These are the current guidelines for the evaluation and management of dyslipidemia in Adults from the National Cholesterol Education Panel.
   Google Scholar
• Batterham MJ, Brown D, Workman C: Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia. AIDS 17, 1414–1416 (2003)
   Google Scholar
• Barrios A, Blanco F, Garcia-Benayas T et al.: Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16, 2079–2081 (2002)
   Google Scholar
• Gavrila A, Tsiodras S, Doweiko J et al.: Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin. Infect. Dis. 36, 1593–1601 (2003)
   Google Scholar
• Yarasheski KE, Tebas P, Stanerson B et al.: Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J. Appl. Physiol. 90, 133–138 (2001)
   Google Scholar
• Saag MS, Powderly WG, Schamelan M et al.: Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Top. HIV Med. 10, 47–51 (2002)
   Google Scholar
• Drechsler H, Powderly WG: Switching effective antiretroviral therapy: a review. Clin. Infect. Dis. 35, 1219–1230 (2002)
   Google Scholar
• Milinkovic A, Martinez E, Lopez S et al.: The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir. Ther. 12, 407–415 (2007)
   Google Scholar
• Llibre JM, Domingo P, Palacios R et al.: Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 20, 1407–1414 (2006)
   Google Scholar
• Valdez JR, Cassetti I, Suleiman JM et al.: The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1- infected patients: three-year follow-up after switching therapy. HIV Clin. Trials 8, 381–390 (2007)
   Google Scholar
• Bennett MT, Johns KW, Bondy GP: Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 6, 15 (2007)
   Google Scholar
• Wohl DA, Tien HC, Busby M et al.: Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. 41, 1498–1504 (2005)
   Google Scholar
• Carter VM, Woolley I, Jolley D, Nyulasi I, Mijch A, Dart A: A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex. Health 3, 287–290 (2006)
   Google Scholar
• Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583–1592 (2001)
   Google Scholar
• Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160–1164 (2001)
   Google Scholar
• Knopp RH: Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498–511 (1999)
   Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569–577 (2002)
   Google Scholar
• Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al.: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. 39, 307–312 (2005).
   Google Scholar
• Penzak SR, Chuck SK, Stajich GV: Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 20, 1066–1071 (2000)
   Google Scholar
• Chapman MJ, McTaggart F: Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler. Suppl. 2, 33–36; discussion 36–37 (2002)
   Google Scholar
• Aberg JA, Zackin RA, Brobst SW et al.: A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIVinfected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res. Hum. Retroviruses 21, 757–767 (2005)
   Google Scholar
• Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG: Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15, 1503–1508 (2001)
   Google Scholar
• Stein JH, Merwood MA, Bellehumeur JL et al.: Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am. Heart J. 147, E18 (2004)
   Google Scholar
• Benesic A, Zilly M, Kluge F et al.: Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 32, 229–233 (2004)
   Google Scholar
• Edwards JE, Moore RA: Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam. Pract. 4, 18 (2003).
   Google Scholar
• This meta-analysis analyzed the effects of different statins on cholesterol end points.
   Google Scholar
• Sekar V, Spinosa-Guzman S, Marien K et al.: Pharmacokinetic drug–drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. Presented at: The 8th International Workshop on Pharmacology of HIV Therapy. Budapest, Hungary, 16–18 April (2007) (Abstract)
   Google Scholar
• Kapur NK: Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev. Cardiovasc. Ther. 5, 161–175 (2007)
   Google Scholar
• Calza L, Colangeli V, Manfredi R et al.: Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 19, 1103–1105 (2005)
   Google Scholar
• Johns KW, Bennett MT, Bondy GP: Are HIV+ patients resistant to statin therapy? Lipids Health Dis. 6, 27 (2007)
   Google Scholar
• Van Der Lee M, Vogel M, Schippers E et al.: Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February (2006) (Abstract 588)
   Google Scholar
• Asberg A, Holdaas H: Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev. Cardiovasc. Ther. 2, 641–652 (2004)
   Google Scholar
• Doser N, Kubli S, Telenti A et al.: Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 16, 1982–1983 (2002)
   Google Scholar
• Palacios R, Santos J, Gonzalez M et al.: Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 30, 536–537 (2002)
   Google Scholar
• Murillas J, Martin T, Ramos A, Portero JL: Atorvastatin for protease inhibitorrelated hyperlipidaemia. AIDS 13, 1424–1425 (1999)
   Google Scholar
• Bonnet F, Balestre E, Thiebaut R et al.: Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999–2001. HIV Med. 5, 133–139 (2004)
   Google Scholar
• Calza L, Manfredi R, Chiodo F: Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17, 851–859 (2003)
   Google Scholar
• Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG: Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am. J. Cardiol. 91, 11C–17C; discussion 17C–19C (2003)
   Google Scholar
• Palacios R, Santos J, Gonzalez M et al.: Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31, 251–253 (2002)
   Google Scholar
• Badiou S, De Boever MC, Dupuy AM, BaillatV, Cristol JP, Reynes J: Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 172, 273–279 (2004)
   Google Scholar
• Caramelli B, de Bernoche CY, Sartori AM et al.: Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz. J. Infect. Dis. 5, 332–338 (2001)
   Google Scholar
• Hewitt RG, Shelton MJ, Esch LD: Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS 13, 868–869 (1999)
   Google Scholar
• Miller J, Brown D, Amin J et al.: A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16, 2195–2200 (2002)
   Google Scholar
• Rao A, D’Amico S, Balasubramanyam A, Maldonado M: Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am. J. Med. Sci. 327, 315–318 (2004)
   Google Scholar
• Manfredi R, Chiodo F: Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. 42, 181–188 (2001)
   Google Scholar
• Calza L, Manfredi R, Chiodo F: Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 30, 26–31 (2002)
   Google Scholar
• Calza L, Manfredi R, Colangeli Vet al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19, 1051–1058 (2005)
   Google Scholar
• Stein E, Stender S, Mata P et al.: Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. 148, 447–455 (2004)
   Google Scholar
• Farnier M, Freeman MW, Macdonell G et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26, 897–905 (2005)
   Google Scholar
• Negredo E, Molto J, Puig J et al.: Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 20, 2159–2164 (2006)
   Google Scholar
• Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L: Ezetimibe effectively decreases LDL-cholesterol in HIVinfected patients. AIDS 20, 1675–1677 (2006).
   Google Scholar
• Gerber MT, Mondy KE, Yarasheski KE et al.: Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin. Infect. Dis. 39, 419–425 (2004)
   Google Scholar
• De Truchis P, Kirstetter M, Perier A et al.: Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J. Acquir. Immune Defic. Syndr. 44, 278–285 (2007)
   Google Scholar
• Gerber JG, Kitch DW, Fichtenbaum CJ et al.: Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J. Acquir. Immune Defic. Syndr. doi: 10.1097/QA1.Ob013e31815bace2 (2007) (Epub ahead of print)
   Google Scholar
• Bailey CJ: Biguanides and NIDDM. Diabetes Care 15, 755–772 (1992)
   Google Scholar
• Hadigan C, Corcoran C, Basgoz N, Davis P Sax B, Grinspoon S: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284, 472–477 (2000)
   Google Scholar
• Hadigan C, Rabe J, Grinspoon S: Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 87, 4611–4615 (2002)
   Google Scholar
• Tomazic J, Karner P, Vidmar L, Maticic M, Sharma PM, Janez A: Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerol. Alp. Panonica. Adriat. 14, 99–105 (2005)
   Google Scholar
• Yki-Jarvinen H: Thiazolidinediones. N. Engl. J. Med. 351, 1106–1118 (2004)
   Google Scholar
• Cavalcanti RB, Raboud J, Shen S, Kain KC, CheungA, Walmsley S: A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J. Infect. Dis. 195, 1754–1761 (2007)
   Google Scholar
• Carr A, Workman C, Carey D et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363, 429–438 (2004)
   Google Scholar
• Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med. 140, 786–794 (2004)
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005)
   Google Scholar
• Dube MP, Wu JW, Aberg JA et al.: Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir. Ther. 11, 1081–1089 (2006).
   Google Scholar